What is Collegium Pharmaceutical, Inc.'s market cap?

Collegium Pharmaceutical, Inc. (COLL) has a market capitalization of $1.2B and trades on NASDAQ.

What is Collegium Pharmaceutical, Inc.'s revenue and profitability?

Collegium Pharmaceutical, Inc. generated $796.3M in trailing twelve-month revenue with net income of $74.9M, representing a net margin of 9.4%. Gross margin stands at 60.7%, with free cash flow of $329.8M. These figures are based on the Q1 2026 filing.

Who are Collegium Pharmaceutical, Inc.'s competitors?

Collegium Pharmaceutical, Inc.'s key competitors include Indivior, Avanos Medical, Inc., Ensysce Biosciences, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Collegium Pharmaceutical, Inc. partner with?

Collegium Pharmaceutical, Inc.'s notable partners include Hikma Pharmaceuticals USA Inc., RADARS System, Inflexxion.

What subsidiaries does Collegium Pharmaceutical, Inc. have?

Collegium Pharmaceutical, Inc.'s subsidiaries include Ironshore Therapeutics.

Where is Collegium Pharmaceutical, Inc. headquartered?

Collegium Pharmaceutical, Inc. is headquartered in United States of America and employs approximately 197 people. It has been publicly traded since 2015.

Collegium Pharmaceutical, Inc.

COLL

Market cap

$1.15B+16.7%

Revenue$796.3M+19.9%

Net income$74.9M+70.8%

Free cash flow$329.8M+60.3%

EPS (diluted)$2.04+67.2%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$193.5MBeat by $9.0M EPS$1.76Beat by $0.24

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$199.6M

EPS estimate$1.68

Financials

Q1 2026

Income statement

See full

Revenue$193.5M+8.9%

Gross profit$117.2M+20.5%

Operating income$30.9M+42.5%

Net income$14.5M+500%

EPS (diluted)$0.40+471%

Balance sheet

See full

Cash & equivalents$289.6M+147%

Total debt$5.2M-19.5%

Total equity$312.4M+33.3%

Total assets$1.7B+1.3%

Cash flow

See full

Operating cash flow$57.1M+3.1%

CapEx$270.0K-66.2%

Free cash flow$56.8M+4.1%

Valuation & ratios

Valuation

See full

Market cap$1.15B+16.7%

Enterprise value$867.73M-3.2%

P/E15.4×-12.4×

P/S1.5×0.0×

Profitability

See full

Gross margin60.7%+3.0pp

Operating margin23.7%+2.3pp

Net margin9.4%+2.8pp

FCF margin41.4%+10.4pp

Returns & leverage

See full

Return on equity27.4%+8.2pp

Debt / equity0×0.0×

Current ratio1.7×+0.6×

Segments

By product

See full

Belbuca$52.6M+1.9%

Xtampza ER$50.8M—

Jornay PM$38.9M+36.3%

Nucynta IR$26.1M-4.9%

Nucynta ER$18.2M-7.4%

By segment

See full

Segment$193.5M+8.9%

Competitors

By market cap

Indivior Pharmaceuticals, Inc. $4.7B+122%

Collegium Pharmaceutical, Inc.$1.2B+14.3%

Bioventus$843.5M+94.7%

Heron Therapeutics$86.9M-69.4%

Dogwood Therapeutics$51.5M-56.9%

Scilex Holding Company$49.4M-43.6%

MIRA Pharmaceuticals, Inc.$37.1M+16.7%

Ensysce Biosciences, Inc.$4.0M-26.0%

By revenue growth

Collegium Pharmaceutical, Inc.+19.9%

Indivior Pharmaceuticals, Inc. +10.3%

Bioventus+1.5%

Scilex Holding Company-33.2%

By net margin

Indivior Pharmaceuticals, Inc. 19.44%+20.0pp

Collegium Pharmaceutical, Inc.9.41%+2.8pp

Bioventus4.94%+10.9pp

Scilex Holding Company-1,162.43%-1,015pp

Profile

Collegium Pharmaceutical is a diversified biopharmaceutical company focused on developing and commercializing differentiated products for serious medical conditions, specifically in the areas of pain management and neuropsychiatry. The company leverages proprietary technology platforms and strategic acquisitions to provide treatments for moderate to severe pain and attention deficit hyperactivity disorder (ADHD). Its core value proposition centers on offering abuse-deterrent formulations and unique dosing schedules to improve patient outcomes and safety.

Competitive position

A leading player in the abuse-deterrent opioid market with a growing presence in the ADHD stimulant market through differentiated delivery technologies.

GeographiesUnited States

Customer segmentsHealthcare providers, Retail pharmacies, Pharmaceutical wholesalers

Business modelProduct-based, Intellectual property licensing, Research and development

SuppliersActive pharmaceutical ingredient (API) suppliers, Contract manufacturing organizations, Specialized chemical suppliers for DETERx technology

CustomersWholesale drug distributors, Specialty pharmacies, Retail pharmacy chains, Healthcare systems

CountryUnited States of America

Listed2015

Employees197.0

CEOVikram Karnani

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Websitecollegiumpharma.com

FilingsSEC EDGAR

Ask your AI about Collegium Pharmaceutical, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Collegium Pharmaceutical, Inc.'s market cap?: Collegium Pharmaceutical, Inc. (COLL) has a market capitalization of $1.2B and trades on NASDAQ.
What is Collegium Pharmaceutical, Inc.'s revenue and profitability?: Collegium Pharmaceutical, Inc. generated $796.3M in trailing twelve-month revenue with net income of $74.9M, representing a net margin of 9.4%. Gross margin stands at 60.7%, with free cash flow of $329.8M. These figures are based on the Q1 2026 filing.
Who are Collegium Pharmaceutical, Inc.'s competitors?: Collegium Pharmaceutical, Inc.'s key competitors include Indivior, Avanos Medical, Inc., Ensysce Biosciences, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Collegium Pharmaceutical, Inc. partner with?: Collegium Pharmaceutical, Inc.'s notable partners include Hikma Pharmaceuticals USA Inc., RADARS System, Inflexxion.
What subsidiaries does Collegium Pharmaceutical, Inc. have?: Collegium Pharmaceutical, Inc.'s subsidiaries include Ironshore Therapeutics.
Where is Collegium Pharmaceutical, Inc. headquartered?: Collegium Pharmaceutical, Inc. is headquartered in United States of America and employs approximately 197 people. It has been publicly traded since 2015.